Karthikeyan Murugesan
Overview
Explore the profile of Karthikeyan Murugesan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
788
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
G Singh P, Jain A, Sridhara Setty P, Bv S, Patil S, P A, et al.
Bioinformation
. 2023 Jun;
18(8):683-691.
PMID: 37323557
There is a shred of evidence to suggest that Emblica officinalis Gaertn, the botanical name for amla seeds, has greater medicinal potential than amla fruit. We conducted this work to...
12.
Jardim D, Murugesan K, Elvin J, Huang R, Kurzrock R
J Immunother Cancer
. 2023 Feb;
11(2).
PMID: 36849197
PD-L1 (CD274) amplification occurs in a small subset of malignancies and may predict anti-PD-1/PD-L1 immunotherapy responsiveness. We hypothesized that both copy number (CN) and focality of cancer-related PD-L1 amplifications impact...
13.
Huang R, Carbone D, Li G, Schrock A, Graf R, Zhang L, et al.
J Immunother Cancer
. 2023 Jan;
11(1).
PMID: 36650021
Background: For patients with advanced non-small cell lung carcinoma (NSCLC), immune checkpoint inhibitor (ICPI) and chemotherapy (chemo) ICPI represent two distinct first-line standard-of-care regimens without clear and established biomarkers to...
14.
Hoskins E, Samorodnitsky E, Wing M, Reeser J, Hopkins J, Murugesan K, et al.
JCO Precis Oncol
. 2023 Jan;
7:e2200300.
PMID: 36623238
Purpose: Programmed cell death protein-1 (PD-1) receptor and ligand interactions are the target of immunotherapies for more than 20 cancer types. Biomarkers that predict response to immunotherapy are microsatellite instability,...
15.
Kendre G, Murugesan K, Brummer T, Segatto O, Saborowski A, Vogel A
J Hepatol
. 2022 Dec;
78(3):614-626.
PMID: 36528236
Background & Aims: In recent years, intrahepatic cholangiocarcinoma (iCCA) has evolved as a "role model" for precision oncology in gastrointestinal cancers. However, its rarity, paired with its genomic heterogeneity, challenges...
16.
Sivakumar S, Jin D, Tukachinsky H, Murugesan K, McGregor K, Danziger N, et al.
Nat Commun
. 2022 Dec;
13(1):7495.
PMID: 36470901
Pathological and genomic profiling have transformed breast cancer care by matching patients to targeted treatments. However, tumors evolve and evade therapeutic interventions often through the acquisition of genomic mutations. Here...
17.
Chen J, Murugesan K, Newberg J, Sokol E, Savage H, Stout T, et al.
JCO Precis Oncol
. 2022 Nov;
6:e2200341.
PMID: 36446041
Purpose: Understanding the differences in biomarker prevalence that may exist among diverse populations is invaluable to accurately forecast biomarker-driven clinical trial enrollment metrics and to advance inclusive research and health...
18.
Kabeerdass N, Murugesan K, Arumugam N, Almansour A, Kumar R, Djearamane S, et al.
Nanomaterials (Basel)
. 2022 Aug;
12(16).
PMID: 36014624
The aqueous extract of (As) acts as the precursors for the quick reduction of silver ions, which leads to the formation of silver nanoparticles. In the agar, well diffusion method...
19.
Furman C, Puyang X, Zhang Z, Wu Z, Banka D, Aithal K, et al.
Mol Cancer Ther
. 2022 Jun;
21(6):890-902.
PMID: 35642432
Summary: H3B-6545 is an ERα covalent antagonist that exhibits encouraging preclinical activity against CDK4/6i naïve and resistant ERαWT and ERαMUT tumors.
20.
Huang R, Harries L, Decker B, Hiemenz M, Murugesan K, Creeden J, et al.
Oncologist
. 2022 May;
27(10):839-848.
PMID: 35598205
Background: In patients with non-small cell lung cancer (NSCLC), 10%-40% will eventually develop brain metastases. We present the clinicopathologic, genomic, and biomarker landscape of a large cohort of NSCLC brain...